Lipoic acid for Alzheimer's disease

Gerald Münch, Lynne Shinto, Annette Maczurek

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

AD affects a growing number of elderly people. At the moment, the most widely used medications (acetylcholinesterase inhibitors) deliver only symptomatic benefits. LA treatment has been shown to reduce markers of oxidative stress and to improve cognitive function in aged animals. The promising results found for combined omega-3 fatty acid and LA supplementation in the double-blind RCT and for LA alone in the open trial in delaying cognitive decline warrant further investigation of LA in combination with other anti-inflammatory compounds for the treatment of AD. Further research should include longer studies, conducted with patients in different stages of the disease.

Original languageEnglish (US)
Pages (from-to)62-64
Number of pages3
JournalMedicine Today
Volume11
Issue number11
StatePublished - Nov 2010

Fingerprint

Thioctic Acid
Alzheimer Disease
Cholinesterase Inhibitors
Omega-3 Fatty Acids
Cognition
Oxidative Stress
Anti-Inflammatory Agents
Therapeutics
Research
Cognitive Dysfunction

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Münch, G., Shinto, L., & Maczurek, A. (2010). Lipoic acid for Alzheimer's disease. Medicine Today, 11(11), 62-64.

Lipoic acid for Alzheimer's disease. / Münch, Gerald; Shinto, Lynne; Maczurek, Annette.

In: Medicine Today, Vol. 11, No. 11, 11.2010, p. 62-64.

Research output: Contribution to journalArticle

Münch, G, Shinto, L & Maczurek, A 2010, 'Lipoic acid for Alzheimer's disease', Medicine Today, vol. 11, no. 11, pp. 62-64.
Münch G, Shinto L, Maczurek A. Lipoic acid for Alzheimer's disease. Medicine Today. 2010 Nov;11(11):62-64.
Münch, Gerald ; Shinto, Lynne ; Maczurek, Annette. / Lipoic acid for Alzheimer's disease. In: Medicine Today. 2010 ; Vol. 11, No. 11. pp. 62-64.
@article{9c91e4abcb68434fa449cd253e5165a3,
title = "Lipoic acid for Alzheimer's disease",
abstract = "AD affects a growing number of elderly people. At the moment, the most widely used medications (acetylcholinesterase inhibitors) deliver only symptomatic benefits. LA treatment has been shown to reduce markers of oxidative stress and to improve cognitive function in aged animals. The promising results found for combined omega-3 fatty acid and LA supplementation in the double-blind RCT and for LA alone in the open trial in delaying cognitive decline warrant further investigation of LA in combination with other anti-inflammatory compounds for the treatment of AD. Further research should include longer studies, conducted with patients in different stages of the disease.",
author = "Gerald M{\"u}nch and Lynne Shinto and Annette Maczurek",
year = "2010",
month = "11",
language = "English (US)",
volume = "11",
pages = "62--64",
journal = "Medicine Today",
issn = "1443-430X",
publisher = "Medicine Today Pty Ltd",
number = "11",

}

TY - JOUR

T1 - Lipoic acid for Alzheimer's disease

AU - Münch, Gerald

AU - Shinto, Lynne

AU - Maczurek, Annette

PY - 2010/11

Y1 - 2010/11

N2 - AD affects a growing number of elderly people. At the moment, the most widely used medications (acetylcholinesterase inhibitors) deliver only symptomatic benefits. LA treatment has been shown to reduce markers of oxidative stress and to improve cognitive function in aged animals. The promising results found for combined omega-3 fatty acid and LA supplementation in the double-blind RCT and for LA alone in the open trial in delaying cognitive decline warrant further investigation of LA in combination with other anti-inflammatory compounds for the treatment of AD. Further research should include longer studies, conducted with patients in different stages of the disease.

AB - AD affects a growing number of elderly people. At the moment, the most widely used medications (acetylcholinesterase inhibitors) deliver only symptomatic benefits. LA treatment has been shown to reduce markers of oxidative stress and to improve cognitive function in aged animals. The promising results found for combined omega-3 fatty acid and LA supplementation in the double-blind RCT and for LA alone in the open trial in delaying cognitive decline warrant further investigation of LA in combination with other anti-inflammatory compounds for the treatment of AD. Further research should include longer studies, conducted with patients in different stages of the disease.

UR - http://www.scopus.com/inward/record.url?scp=78649363436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649363436&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 62

EP - 64

JO - Medicine Today

JF - Medicine Today

SN - 1443-430X

IS - 11

ER -